Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Drug Shortages Plague The U.S., Could India’s Strides Be Looking To Sell?

This article was originally published in PharmAsia News

Executive Summary

Aided by an acute drug shortage in the U.S., Agila, the injectables business of Strides, has grown rapidly, sparking speculation of a buyout from a global bidder. PharmAsia News takes a closer look.


Related Content

Drug Shortages Mostly FDA’s Fault, House Oversight Committee Concludes
Pfizer, Strides Arcolab Join Forces To Manufacture And Market Oncology Injectables In U.S.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts